Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MEI Pharma, Inc. (MEIP : NSDQ)
 
 • Company Description   
MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego.

Number of Employees: 28

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.69 Daily Weekly Monthly
20 Day Moving Average: 23,883 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: 0.19
52 Week High: $4.10
52 Week Low: $1.46
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 19.03% 14.95%
12 Week 36.84% 15.48%
Year To Date 9.35% 2.41%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9920 Pacific Heights Blvd. Suite 150
-
SAN DIEGO,CA 92121
USA		 ph: 858-369-7100
fax: 302-655-5049		 investor@meipharma.com http://www.meipharma.com
 
 • General Corporate Information   
Officers
David M. Urso - President and Chief Executive Officer
Justin J. File - Chief Financial Officer
James Flynn - Director
Taheer Datoo - Director
Thomas C. Reynolds - Director

Peer Information
MEI Pharma, Inc. (GSAC)
MEI Pharma, Inc. (CASI)
MEI Pharma, Inc. (ALCD.)
MEI Pharma, Inc. (OMNN)
MEI Pharma, Inc. (CGPI.)
MEI Pharma, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 55279B301
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 09/18/25
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 4.00 (0.05:1)
Beta: 0.19
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/18/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.92
Price/Cash Flow: 0.45
Price / Sales: -
EPS Growth
vs. Year Ago Period: 71.53%
vs. Previous Quarter: 18.75%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -77.00
12/31/24 - -78.39
ROA
06/30/25 - -
03/31/25 - -64.79
12/31/24 - -61.22
Current Ratio
06/30/25 - -
03/31/25 - 16.78
12/31/24 - 4.88
Quick Ratio
06/30/25 - -
03/31/25 - 16.78
12/31/24 - 10.66
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 2.93
12/31/24 - 4.96
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©